1. Perrillo RP; The role of liver biopsy in hepatilis C. Hepatology; 1997; 26:57.
2. EASL Inlernatİonal Consensus Conference on Hepatilis C: Paris, February 26-27, 1999. Consensus statcnıent. J Hepatol; 1999; 31: 3.
3. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in Fraııce:resui!s of a prospective nationwide survey. For the Group of Epidemİology of tlıe French Associatioıı for the Study of the Liver (AFEF). Hepatology; 2000; 32: 477.
4. Froehlich F, Lamy O, Fried M, Gonvcrs JJ: Practice and conıplicalions of liver biopsy. Resulls of a ııationvvide survey in Switzerland. Dig Dis Sci; 1993; 38: 1480.
5. McGill DB, Rakela J, Zinsmeistcr AR, Ott BJ: A 21 -year experience with raajor hemorrhage afler percutaneous liver biopsy. Gastroenterology; 1990; 99: 1396.
6. Oberti F, Valsesia E, Pİleltc C et al: Noninvazive diagnosis of hepalic fibrosis or cirrhosis. Gastroenterology; 1997;Î13; 1609.
7. Tran A, Hastier P, Barjoan EM et al: Non invasive pre-diclion of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol.; 2000; 24: 626.
ü. Leroy V, Traversay C, Barnoud R ct al: Changes in his-tological lesions and serum fibrogene.sis markers in ehronic hepatitis C patients tıoıı-rcsponders to interferoıı- ?. J Hepatol.; 2001; 35:120.
9. Ishtbashi K, Kaslıiwagi T, Ito A el al: Changes İn serum fibrogenesis markers during inteıferon therapy for ehronic heaptilis type C. Hepatology; 1996; 1:27.
10. Murawaki Y, Ikula Y, Okamolo K et al: Diagııostic value of serum markers of conneclive tissue tumover lor pre-dicling hislological slaging and grading in patients wilh ehronic hepatilis C. J Gastroenteroi; 2001; 6: 399.
11. Myers RP, Ratziu V, Imbeıt-Bismul F, Charlotte F, Poy-nard T: Biochemical markers of liver fivrosis: A compa-rison wilh lıistortcal icatures İn patients vvitb ehronic hc-patitis C. The MULTIVIRC group. Ara J Gastroenterol; 2002; 97: 2419.
12. Myers RP, De Torres M, Imberl-Bismut F, Ratziu V, Charlotte F, Poynaıd T: Biochemical markers of fibrosis in patients with ehronic hepatitis C. The MULTIVIRC group. Dig Dis Sci; 42003; 8: 146.
13. Lu LG, Zeng M D, Wan MB, Li CZ, Mao YM, Li JQ, Oiu DK, Cao AP, Ye J, Cai X, Chen CW, VVaııg JY, Wu SM, Zhu JS, Zhou XQ; Grading and stagtng of hepalic fibrosis, and its reiationship witb noninvasive diagnostic paramelers. World J Gastroenterol; 2003; 9: 2574.
14. Ramadori G, Zoehrens G, Manns MP, Rider H, Dicnes HP, Hess G, Meyer-z. Buescbenfelde KH: Serum hyalıı-ronate and type III procollagen aminoterminal propeptide concentralion in ehronic liver disease. Reiationship to
cirrhosis and disease aetivity. Eur J Clin Invest 1991; 21:323.
15. Sotaniemi EA, Mungan Z, Ristelli J et al: Serum type III procollagen and basement membrane antigens in hepatitis B virüs liver disease. Euro J İnternal Mcd.; 1992; 3:131.
16. Tcare JP, Sherman D, Greenfield SM et al: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancel; 1993; 342:895.
17. Jeröme G, Rence EP, Philİppe G et al: Reiationship bet-ween procollagen III aminoterminal propeptide and hya-luronan serum levels and histological fibrosis in primary biliary cirrhosis and ehronic vira! hepatitis C. J Hepatol.; 1994;20:388.
18. Takato U, Sadalaka I, Michİo S et al: Serum hyaluronate predicts response to interferon-? therapy in patients wilh ehronic hepatilis C. Hepato-Gaslroentcrology; 1995; 42:522.
19. Jeffers JL, Coelho-Litfie EM, Cheİnquer H et al: Procol-tagcn-III peptide and ehronic viral C hepatilis. Am J Gastroenterol.; 1995; 9: 1437.
20. Guechot J, Poupon RE, Ponpon R: Serum hyaluronan as a marker of liver fibrosis. J Hepatol.; 1995; 22:103.
21. Jeröme G, Loria A, Serfaty L et al: Serum hyaluronan as a marker of liver fibrosis in ehronic viral hepatitis C: ef-fcet of ?-iııterfcron therapy. J Hepatol. 1995; 22: 22.
22. Slickel F, Urbaschek R, Schuppan D, Pocschl G, Oester-ling C, Conradt C, Mccuskey RS, Simanowski UA and Settz HK: Serum collagen Type VI and XIV and hyalu-ronic acid as early sndicators for altcred conneclive tissue (urnover in alcoholic liver disease. Dig Dis Sci; 2001; 46: 2025.
23. Npjgaard C, Johansen JS, Christensen E, Skovgaaıd LT, Price PA, Becker U: Serum levels of YKL-40 and PIIINP as prognostic markers in patients wilh alcoholic liver disease. The EMALD group. J Hepatol; 2003; 39: 179.
24. Piletlc C, Rousselet MC, Bedossa P et al: Histopathoio-gical evaluation of liver fibrosis: quanlitative image aualysis vs semi-quaulilatîve scores. J Hepatol.; 1998; 28; 439,
25. Thabut D, Simoıı M, Myers RP, Messous D, Thiibault V, Imberl-Bismuth F, Poynard T: Noninvasive predicüon of fibrosis in palienfs wilh ehronic lıepatitis C. Hepatology; 2003;37:1220.
26. Korner T, Kropf J, Kosche B, Kristali! II, Jaspersen D, Gressner AM: Improvemenl of prognostic powcr of the Chİld-Pugh elassification of liver cirrhosis by hyaluronan. J Hepatol; 2003; 39: 947.
27. Min Zheng, Wei-Min Cai, Hong-Lei Weng, Rong-Hııa Liu: ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol; 2002; 8:1073.
28. The French METAVİR Cooperativc Study Group. Inlıa-observer and interobserver variations in liver biopsy in-terpretation in patienls wilh ehronic hepatitis C. Hepalo-logy. 1994; 20:15.
29. Knodell RG, Ishak KG, Black WC et al: Formulation and application of numerical scoring systcın for accessing histologycal aetivity in asymtomalic ehronic aetive hepatitis. Hepatology. 198L; 1:431.
30. Nord HJ: Biopsy diagnosis of cirrhosis: blind percutaneous versııs guided direct vision lechniqucs - a review. GastrointestEndosc; 1982; 28: 102.
Thank you for copying data from http://www.arastirmax.com